Libaccord Overview
Libaccord is the developer of an innovative device for treating ventricular and atrial arrhythmias using super-cooled liquid nitrogen. Based on the deepest possible ablation (transmural), the companys solution uses the novel clinical approach of scar homogenization to reduce procedure time and includes built-in ablation depth feedback to ensure performance and safety.
Latest News
growth-positive
עם היד (הטכנולוגית) על הדופק
The article discusses the issue of heart rhythm disorders, which affects millions of people worldwide. It highlights the work of Dr. Gregory Golobchiner, who is involved with two startups, CardioKol and LibAccord. CardioKol has developed a technology that uses an app to detect atrial fibrillation based on a persons voice. LibAccord, on the other hand, is developing a technique for ablating heart rhythm disorders. Both technologies aim to improve early detection and treatment of heart rhythm disorders.
CustomersPartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | libaccord.com/ |
Locations
Haifa, Israel
Photos & Videos
No files yet
